These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
238 related articles for article (PubMed ID: 3096792)
21. Impact of clomiphene citrate during ovarian stimulation on the luteal phase after GnRH agonist trigger. Derksen L; Tournaye H; Stoop D; Van Vaerenbergh I; Bourgain C; Polyzos NP; Haentjens P; Blockeel C Reprod Biomed Online; 2014 Mar; 28(3):359-68. PubMed ID: 24456700 [TBL] [Abstract][Full Text] [Related]
22. Induction of ovulation in the patient with polycystic ovarian disease. Blankstein J; Quigley MM Endocrinol Metab Clin North Am; 1988 Dec; 17(4):733-49. PubMed ID: 3143566 [TBL] [Abstract][Full Text] [Related]
23. Use of combined exogenous gonadotropins and pulsatile gonadotropin-releasing hormone in patients with polycystic ovarian disease: a new approach to induction of ovulation. Venturini PL; Remorgida V; Anserini P; De Cecco L Gynecol Endocrinol; 1988 Sep; 2(3):205-13. PubMed ID: 3147583 [TBL] [Abstract][Full Text] [Related]
25. Tumor necrosis factor alpha versus LH and androstendione as a reliable predictor of spontaneous ovulation after laparoscopic ovarian drilling for women with clomiphene citrate resistance polycystic ovarian disease. Seyam E; Hefzy E Eur J Obstet Gynecol Reprod Biol; 2018 Mar; 222():126-133. PubMed ID: 29408743 [TBL] [Abstract][Full Text] [Related]
26. [Induction of ovulation with pulsatile LHRH in anovulatory women]. Masaoka K; Kumasaka T Nihon Sanka Fujinka Gakkai Zasshi; 1984 Jun; 36(6):937-46. PubMed ID: 6431037 [TBL] [Abstract][Full Text] [Related]
27. Characterization of the inappropriate gonadotropin secretion in polycystic ovary syndrome. Rebar R; Judd HL; Yen SS; Rakoff J; Vandenberg G; Naftolin F J Clin Invest; 1976 May; 57(5):1320-9. PubMed ID: 770505 [TBL] [Abstract][Full Text] [Related]
28. Combined use of gonadotropin-releasing hormone and its analogues for ovulation induction optimization. Filicori M Clin Obstet Gynecol; 1993 Sep; 36(3):737-43. PubMed ID: 8403620 [No Abstract] [Full Text] [Related]
29. Clinical and endocrine effects of laser vaporization in patients with polycystic ovarian disease. Verhelst J; Gerris J; Joostens M; Van der Meer S; Van Royen E; Mahler C Gynecol Endocrinol; 1993 Mar; 7(1):49-55. PubMed ID: 8506763 [TBL] [Abstract][Full Text] [Related]
30. Bromocriptine treatment of women with clomiphene-resistant polycystic ovary syndrome. Polson DW; Mason HD; Franks S Clin Endocrinol (Oxf); 1987 Feb; 26(2):197-203. PubMed ID: 3117444 [TBL] [Abstract][Full Text] [Related]
31. Induction of ovulation in clomiphene-resistant polycystic ovary syndrome with pulsatile GnRH. Tan SL; Farhi J; Homburg R; Jacobs HS Obstet Gynecol; 1996 Aug; 88(2):221-6. PubMed ID: 8692506 [TBL] [Abstract][Full Text] [Related]
32. Inhibition of ovulation in women by chronic treatment with a stimulatory LRH analogue--a new approach to birth control? Nillius SJ; Bergquist C; Wide L Contraception; 1978 Jun; 17(6):537-45. PubMed ID: 352612 [TBL] [Abstract][Full Text] [Related]
33. Pulsatile luteinizing hormone secretion in women with polycystic ovary syndrome under clomiphene citrate. Differences between responders and nonresponders. Sir-Petermann T; Alba F; Cohen P; Pacheco J; Devoto L; Rossmanith W Exp Clin Endocrinol; 1990 Sep; 96(1):45-51. PubMed ID: 2126241 [TBL] [Abstract][Full Text] [Related]
34. [Ovulation induction with pulsatile gonadotropin-releasing hormone and continuous human menopausal gonadotropin in polycystic ovarian disease]. Kuroda G Nihon Naibunpi Gakkai Zasshi; 1987 Mar; 63(3):247-59. PubMed ID: 3111899 [TBL] [Abstract][Full Text] [Related]
35. The effects of buserelin on the hormonal states in PCOD. Willemsen WN; Franssen AM; Rolland R; Vemer HM Prog Clin Biol Res; 1986; 225():377-89. PubMed ID: 3097673 [No Abstract] [Full Text] [Related]
36. Pharmaco-dynamics of human menopausal gonadotrophin (HMG) and follicle-stimulating hormone (FSH). The importance of the FSH concentration in initiating follicular growth in polycystic ovary-like disease. van Weissenbruch MM; Schoemaker HC; Drexhage HA; Schoemaker J Hum Reprod; 1993 Jun; 8(6):813-21. PubMed ID: 8345068 [TBL] [Abstract][Full Text] [Related]
37. Ovulation induction in clomiphene-resistant anovulatory women: differential follicular response to purified urinary follicle-stimulating hormone (FSH) versus purified urinary FSH and luteinizing hormone. Hoffman DI; Lobo RA; Campeau JD; Tsai HM; Holmberg EA; Ono T; Frederick JJ; Platt LD; diZerega GS J Clin Endocrinol Metab; 1985 May; 60(5):922-7. PubMed ID: 3920235 [TBL] [Abstract][Full Text] [Related]
39. Adjusting the dose to the individual response of the patient during the induction of ovulation with pulsatile gonadotropin-releasing hormone. Mais V; Melis GB; Strigini F; Antinori D; de Ruggiero A; Fioretti P Fertil Steril; 1991 Jan; 55(1):80-5. PubMed ID: 1898894 [TBL] [Abstract][Full Text] [Related]
40. Benefits of continuous physiological pulsatile gonadotropin-releasing hormone therapy in women with polycystic ovarian syndrome. Corenthal L; Von Hagen S; Larkins D; Ibrahim J; Santoro N Fertil Steril; 1994 Jun; 61(6):1027-33. PubMed ID: 8194612 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]